Last edition
News about " ACCRUFeR "
Soleno Withdraws EU Filing for Rare Disease Drug Ahead of Neurocrine Takeover
Soleno Therapeutics has withdrawn its European marketing application for Vykat XR, a treatment for hyperphagia associated with Prader-Willi syndrome, ahead of its planned acquisition by Neurocrine Biosciences.
ACCRUFeR | 09/04/2026 | By Darshana
Shield Therapeutics secures expanded U.S. Food and Drug Administration approval for ACCRUFeR (ferric maltol) to treat iron deficiency in pediatric patients aged 10 and above, addressing a major unmet need.
ACCRUFeR | 20/02/2026 | By News Bureau | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy